214 related articles for article (PubMed ID: 32862040)
1. NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS.
Novakova L; Axelsson M; Malmeström C; Zetterberg H; Blennow K; Svenningsson A; Lycke J
Mult Scler Relat Disord; 2020 Nov; 46():102463. PubMed ID: 32862040
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.
Novakova L; Axelsson M; Khademi M; Zetterberg H; Blennow K; Malmeström C; Piehl F; Olsson T; Lycke J
J Neurochem; 2017 Apr; 141(2):296-304. PubMed ID: 27787906
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid neurofilament light chains and CXCL13 as predictive factors for clinical course of multiple sclerosis.
Hradilek P; Revendova KZ; Horakova J; Bunganic R; Pelisek O; Zeman D; Hanzlikova P; Kusnierova P
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2023 Mar; 167(1):30-35. PubMed ID: 36695545
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.
Novakova L; Axelsson M; Khademi M; Zetterberg H; Blennow K; Malmeström C; Piehl F; Olsson T; Lycke J
Mult Scler; 2017 Jan; 23(1):62-71. PubMed ID: 27003946
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
Axelsson M; Malmeström C; Gunnarsson M; Zetterberg H; Sundström P; Lycke J; Svenningsson A
Mult Scler; 2014 Jan; 20(1):43-50. PubMed ID: 23702432
[TBL] [Abstract][Full Text] [Related]
6. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E
J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573
[TBL] [Abstract][Full Text] [Related]
7. Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis.
Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
Eur J Neurol; 2017 May; 24(5):703-712. PubMed ID: 28261960
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.
Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T
PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354
[TBL] [Abstract][Full Text] [Related]
9. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity.
Kuhle J; Barro C; Disanto G; Mathias A; Soneson C; Bonnier G; Yaldizli Ö; Regeniter A; Derfuss T; Canales M; Schluep M; Du Pasquier R; Krueger G; Granziera C
Mult Scler; 2016 Oct; 22(12):1550-1559. PubMed ID: 26754800
[TBL] [Abstract][Full Text] [Related]
10. CSF neurofilament light chain testing as an aid to determine treatment strategies in MS.
Reyes S; Smets I; Holden D; Carrillo-Loza K; Christmas T; Bianchi L; Ammoscato F; Turner B; Marta M; Schmierer K; Giovannoni G; Gnanapavan S
Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32826298
[TBL] [Abstract][Full Text] [Related]
11. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis.
Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
J Neuroinflammation; 2018 Jul; 15(1):209. PubMed ID: 30021640
[TBL] [Abstract][Full Text] [Related]
12. Intrathecally produced CXCL13: A predictive biomarker in multiple sclerosis.
DiSano KD; Gilli F; Pachner AR
Mult Scler J Exp Transl Clin; 2020; 6(4):2055217320981396. PubMed ID: 33403120
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis.
Sellebjerg F; Royen L; Soelberg Sørensen P; Oturai AB; Jensen PEH
Mult Scler; 2019 Oct; 25(11):1444-1451. PubMed ID: 30113249
[TBL] [Abstract][Full Text] [Related]
14. Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.
Bar-Or A; Thanei GA; Harp C; Bernasconi C; Bonati U; Cross AH; Fischer S; Gaetano L; Hauser SL; Hendricks R; Kappos L; Kuhle J; Leppert D; Model F; Sauter A; Koendgen H; Jia X; Herman AE
EBioMedicine; 2023 Jul; 93():104662. PubMed ID: 37354600
[TBL] [Abstract][Full Text] [Related]
15. Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial.
de Flon P; Laurell K; Sundström P; Blennow K; Söderström L; Zetterberg H; Gunnarsson M; Svenningsson A
Acta Neurol Scand; 2019 May; 139(5):462-468. PubMed ID: 30740668
[TBL] [Abstract][Full Text] [Related]
16. Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis.
Gil-Perotin S; Castillo-Villalba J; Cubas-Nuñez L; Gasque R; Hervas D; Gomez-Mateu J; Alcala C; Perez-Miralles F; Gascon F; Dominguez JA; Casanova B
Front Neurol; 2019; 10():1008. PubMed ID: 31608004
[No Abstract] [Full Text] [Related]
17. Fatigue scores correlate with other self-assessment data, but not with clinical and biomarker parameters, in CIS and RRMS.
Håkansson I; Johansson L; Dahle C; Vrethem M; Ernerudh J
Mult Scler Relat Disord; 2019 Nov; 36():101424. PubMed ID: 31586802
[TBL] [Abstract][Full Text] [Related]
18. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
[TBL] [Abstract][Full Text] [Related]
19. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis.
Romme Christensen J; Börnsen L; Khademi M; Olsson T; Jensen PE; Sørensen PS; Sellebjerg F
Mult Scler; 2013 Jun; 19(7):877-84. PubMed ID: 23178691
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies.
Martin SJ; McGlasson S; Hunt D; Overell J
J Neurol Neurosurg Psychiatry; 2019 Sep; 90(9):1059-1067. PubMed ID: 31123141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
